Presentation is loading. Please wait.

Presentation is loading. Please wait.

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma.

Published byたみじろう いまいだ Modified over 5 years ago

Similar presentations

Presentation on theme: "Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma."— Presentation transcript:

1 Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study by Dan T. Vogl, David Dingli, R. Frank Cornell, Carol Ann Huff, Sundar Jagannath, Divaya Bhutani, Rachid Baz, Ajay K Nooka, Joshua Richter, Craig E. Cole, Ravi Vij, Andrzej Jakubowiak, Rafat Abonour, Gary J. Schiller, Terri L. Parker, Luciano J. Costa, David Kaminetzky, James Hoffman, Andrew J. Yee, Ajai Chari, David S. Siegel, Rafael Fonseca, Scott VanWier, Gregory Ahmann, Ilsel Lopez, Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla Picklesimer, Sharon Friedlander, Cassandra Choe-Juliak, and A. Keith Stewart Blood Volume 128(22): December 2, 2016 ©2016 by American Society of Hematology

2 Activity of Sd in Patients with High Risk MM Cytogenetics.
Dan T. Vogl et al. Blood 2016;128:491 ©2016 by American Society of Hematology

Download ppt "Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma."

Similar presentations

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,
Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.
Novel Therapies for Myeloma A. Keith Stewart Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Disclosure of Potential Conflicts of Interest.

Novel Therapies for Myeloma A. Keith Stewart Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Disclosure of Potential Conflicts of Interest.
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways.

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways.
Slideset on: Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone.

Slideset on: Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone.
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S

by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Treatment of Immunoglobulin Light Chain Amyloidosis

Treatment of Immunoglobulin Light Chain Amyloidosis
Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.

Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.
Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma
How I treat multiple myeloma in younger patients

How I treat multiple myeloma in younger patients
Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma by Shigesaburo Miyakoshi, Masahiro Kami,

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma by Shigesaburo Miyakoshi, Masahiro Kami,
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone.

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone.
Clonal competition with alternating dominance in multiple myeloma

Clonal competition with alternating dominance in multiple myeloma
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)  Sundar Jagannath, Rafat Abonour, Brian.

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry ( )  Sundar Jagannath, Rafat Abonour, Brian.

Similar presentations

Ads by Google